Table 1.

Summary of Clinical Characteristics of Melanoma Patients Who Underwent Immune Checkpoint Inhibitor Therapy at the University of Texas Southwestern Medical Center (n = 39)

Dates of Therapy	2016-2017
Age (years)	37-92; median 68
Gender	Female, 9 (23%); Male, 30 (77%)
Ethnicity	37 Caucasian (94%), 1 Hispanic (2%), 1 African-American (2%)
Number of metastatic sites	One, 23 (59%); Two, 13 (33%); Three, 3 (8%)
Metastases site	Adrenal, 3 (8%); Bone, 3 (8%); Liver, 7 (18%); lung, 21 (54%); Lymph nodes, 15 (38%); SQ, 8 (21%)
Antibiotic usage prior to and/or during ICT therapy	3 (8%)
Probiotic therapy	1 (3%)